50735-33-6

Basic information

• Product Name: 2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER
• Synonyms: 2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER;methyl 2-amino-5-chloronicotinate;Methyl 2-aMino-5-chloropyridine-3-carboxylate
• CAS NO: 50735-33-6
• Molecular Formula: C7H7ClN2O2
• Molecular Weight: 186.59568
• Mol File: 50735-33-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER(50735-33-6)
• EPA Substance Registry System: 2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER(50735-33-6)

Safety Data

• Hazardous Substances Data: 50735-33-6(Hazardous Substances Data)

Usage

General Description

2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER is a chemical compound that belongs to the class of nicotinic acid derivatives. It is an ester of 2-amino-5-chloronicotinic acid and methyl alcohol. 2-AMINO-5-CHLORO-NICOTINIC ACID METHYL ESTER is mainly used in the pharmaceutical industry as an intermediate in the synthesis of other organic compounds. It has potential applications in the development of drugs for various medical conditions due to its structural properties and reactivity. It is also used in research and development for the creation of new chemical entities with potential therapeutic benefits. However, this compound should be handled and used with caution, following all safety guidelines and regulations.

Upstream product

• 67754-03-4 methyl 2,5-dichloronicotinate 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 14667-47-1 methyl 2-aminonicotinate 

Downstream Products

• 760144-55-6 methyl 6-chloroimidazol[1,2-a]pyridine-8-carboxylate 
• 151898-33-8 SC 53606 

Relevant articles and documents

EIF4E INHIBITORS AND USES THEREOF

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

HETEROARYL SUBSTITUTED PYRAZINYL-PIPERAZINE-PIPERIDINES WITH CXCR3 ANTAGONIST ACTIVITY

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1 and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non limiting example(s) include, psoriasis), autoimmune diseases (non limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.